Division of Genetic Medicine, Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington, USA.
Manchester Centre for Genomic Medicine, Division of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
J Med Genet. 2019 Feb;56(2):89-95. doi: 10.1136/jmedgenet-2018-105625. Epub 2018 Dec 4.
Kabuki syndrome (KS) is a clinically recognisable syndrome in which 70% of patients have a pathogenic variant in or . Understanding the function of these genes opens the door to targeted therapies. The purpose of this report is to propose diagnostic criteria for KS, particularly when molecular genetic testing is equivocal.
An international group of experts created consensus diagnostic criteria for KS. Systematic PubMed searches returned 70 peer-reviewed publications in which at least one individual with molecularly confirmed KS was reported. The clinical features of individuals with known mutations were reviewed.
The authors propose that a definitive diagnosis can be made in an individual of any age with a history of infantile hypotonia, developmental delay and/or intellectual disability, and one or both of the following major criteria: (1) a pathogenic or likely pathogenic variant in or ; and (2) typical dysmorphic features (defined below) at some point of life. Typical dysmorphic features include long palpebral fissures with eversion of the lateral third of the lower eyelid and two or more of the following: (1) arched and broad eyebrows with the lateral third displaying notching or sparseness; (2) short columella with depressed nasal tip; (3) large, prominent or cupped ears; and (4) persistent fingertip pads. Further criteria for a probable and possible diagnosis, including a table of suggestive clinical features, are presented.
As targeted therapies for KS are being developed, it is important to be able to make the correct diagnosis, either with or without molecular genetic confirmation.
歌舞伎综合征(KS)是一种临床上可识别的综合征,其中 70%的患者在 或 中存在致病性变异。了解这些基因的功能为靶向治疗开辟了大门。本报告的目的是提出 KS 的诊断标准,特别是在分子遗传学检测不确定时。
一组国际专家制定了 KS 的共识诊断标准。系统的 PubMed 搜索返回了 70 篇同行评议的出版物,其中至少有一篇报道了分子上确诊的 KS 个体。审查了具有已知突变个体的临床特征。
作者提出,任何年龄的个体,如果有婴儿期张力减退、发育迟缓/或智力残疾史,且存在以下一个或两个主要标准之一,即可做出明确诊断:(1) 或 中存在致病性或可能致病性变异;(2)在生命的某个阶段具有典型的畸形特征(定义如下)。典型的畸形特征包括长睑裂伴下眼睑外侧三分之一外翻,以及以下两种或两种以上特征:(1)拱形宽眉毛,外侧三分之一有切迹或稀疏;(2)短鼻中隔伴鼻尖凹陷;(3)大而突出或杯状耳朵;(4)持续存在指尖垫。还提出了可能和可能诊断的进一步标准,包括提示临床特征的表格。
随着针对 KS 的靶向治疗方法的发展,重要的是能够做出正确的诊断,无论是否有分子遗传学确认。